OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 75. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Enhancing childhood cancer targetability	710
Shooting for multiplexed pathology with Orion	537
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial	508
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	411
An oncolytic circular RNA therapy	373
Considering molecular alterations as pan-cancer tissue-agnostic targets	330
A low-coverage liquid biopsy for lung cancer	325
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	308
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	291
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	271
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	248
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	208
The cGAS–STING pathway and cancer	193
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	181
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	180
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	156
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	153
MALAT1 protects dormant tumor cells from immune elimination	148
A macrophage-activated abscopal effect	147
Breaking frontiers with multidisciplinary cancer research	140
PARP11 interfer(on)es with CAR T cell efficacy	136
Gut decisions in CAR T cell therapy	135
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	132
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	131
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	129

Palmitate oxidation drives a pro-metastatic post-translational modification	123
Expanding the options for KRAS inhibition	123
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	119
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	119
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	117
Advancing therapeutics in small-cell lung cancer	115
The importance of being generous	115
Shaping the microenvironment in peritoneal metastases	113
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	108
Bone marrow progenitor-like cells against leukemia cure	108
Stress granules shape metabolic reprogramming and drug resistance	108
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	107
Impact of context-dependent autophagy states on tumor progression	107
A molecular glue halts RAS–MAPK signaling	106
Determinants of resistance and response to melanoma therapy	106
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	106
Innate immunity drives epithelial cell plasticity during prostate tumor formation	105
Sarcoma ecotypes determine immunotherapy benefit	104
A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche	103
Antibody avidity meets multiple myeloma	103
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	99
Thriving in diverse ecosystems	99
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	98
Evolving landscape of nasopharyngeal carcinoma therapy	95
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	94
Key insights from ESMO Congress 2025	92
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	91
Inflammation meets translation in AML	91
A comeback for checkpoint inhibition in multiple myeloma	89
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	88
Cycling back to folate metabolism in cancer	86
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	84
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	82
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	82
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	82
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	81
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	80
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	80
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	79
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	79
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	78
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	78
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	77
Radioligand cancer therapy comes to the fore	77
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	76
Multimodal data integration improves immunotherapy response prediction	76
Dual inhibition of EGFR and PI3K with a single drug	76
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	76
Immunotargeting of a recurrent AML-specific neoantigen	75
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	75